Drug intelligence / Profile preview

SP-221-10

Development stage: Preclinical
Lead developer: Shaman Ventures
Modality: Small Molecules

Overview

SP-221-10 is a small molecule drug candidate being developed by Shaman Ventures for the treatment of drug-resistant malaria. Currently in the preclinical stage, the compound was derived from Shaman's research into natural products with medicinal properties. While the specific biological target and mechanism of action remain undisclosed, the program aims to provide new therapeutic options for malaria strains that have developed resistance to existing treatments.

Beyond the preview

Go deeper on SP-221-10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP-221-10.

Explore the full profile